Celltrion Receives European Approval for Phase 3 Clinical Trial of Multiple Myeloma Biosimilar
Celltrion announced on September 1 that it has received approval from the European Medicines Agency (EMA) for its global Phase 3 clinical trial plan for 'CT-P44,' a biosimilar (biopharmaceutical generic) of Darzalex (active ingredient: daratumumab), a treatment for multiple myeloma, a type of blood cancer.
Celltrion plans to demonstrate similarity between Darzalex and CT-P44 through an efficacy and safety comparison study involving a total of 486 patients with refractory and relapsed multiple myeloma over a two-year period.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Darzalex is a targeted anticancer drug that binds to a specific protein present on the surface of multiple myeloma cells, blocking the growth of cancer cells. In 2023, its global sales reached approximately 9.744 billion dollars (about 13.5694 trillion won), and its substance patents are set to expire in the United States in 2029 and in Europe in 2031.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
